Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ed Silverman

Latest From Ed Silverman

Solutions To The AMR ‘Silent Pandemic’ Need More Than Just Lip Service

With new antibiotics a rare commodity, persistently inadequate reimbursement for innovations and worthy but often piecemeal pilots, antimicrobial resistance has quietly risen to become a factor in well over a million deaths annually. Now that COVID-19 is not the all-encompassing threat to health it was until fairly recently, AMR is once again moving towards the center of attention. But properly funded actions and mindset changes are needed.

Infectious Diseases BioPharmaceutical

Under Pressure: Are Enhanced Global Efforts Enough For Trial Transparency?

Increasing scrutiny is being placed on trial sponsors and regulators to improve trial data reporting. Researchers complain that, without access to specific data, results cannot be easily duplicated, which inhibits greater understanding of how medicines might work, adversely affecting treatment decisions and health care costs. Are penalties and public reprimands enough to change behavior?

Clinical Trials Policy

Pharma Versus Hospitals: 340B Battle Continues

Exploring the continued controversy around the 340B US federal drug discount program. As the story moves into 2022, key questions remain unanswered.

Market Access Policy

Civil Society Groups Use COVID To Build Stronger Narrative For Equal Access

The divide between developed and developing countries for access to health care innovations has been spotlighted by the ongoing COVID-19 pandemic. Civil society groups pile on the pressure.

Coronavirus COVID-19 Market Access

Is Pharma Doing Enough To Enable Access To COVID-19 Vaccines Everywhere?

The race to develop COVID-19 vaccines is intensifying long-standing debate over the ability of lower-income countries to gain affordable access to needed medical treatments. Patient advocates argue that drug makers and wealthy governments are striking deals that place poor countries at a disadvantage. The pharmaceutical industry, however, maintains it is moving as quickly as possible to not only discover safe and effective vaccines, but to enable equitable distribution.    

Coronavirus COVID-19 Market Access

Defining Go And No-Go Disease Areas As An R&D Business

Some believe unmet need refers only to rare diseases and tiny patient populations. But it is more than this. In 2020, the term sits at the heart of decision-making for drug makers – along with cost, access and value, of course.

Business Strategies Research & Development
See All
UsernamePublicRestriction

Register